Previous 10 | Next 10 |
home / stock / mycof / mycof news
Mydecine Innovations Group press release (OTCPK:MYCOF): Q1 GAAP EPS of -$1.20 misses by $0.41. As of March 31, 2022, the company had cash and cash equivalents of $0.26M. For further details see: Mydecine Innovations Group GAAP EPS of -$1.20 misses by $0.41
DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financi...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons , the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman says LSD and MDMA helped him alleviate symptoms rel...
Biotechnology company Mydecine Innovations Group (OTCPK:MYCOF) on Wednesday announced a 1-for-50 reverse stock split, wherein every 50 common shares will be consolidated into 1 common share. The reverse stock split is expected to result in Mydecine's outstanding common shares being reduced fr...
Mydecine Announces Reverse Stock-Split Canada NewsWire DENVER , April 13, 2022 /CNW/ - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (" Mydecine " or the " Company "), today announces its Board of Directors has voted in favo...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety med...
In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfo...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic an...
Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an i...
New research has found that the experiences of people who talked about and reported nonsuicidal self-injury on Reddit are similar to individuals who have been diagnosed with substance use disorder. Individuals who posted on a self-injury forum titled r/self-harm in 2010–2019 cited...
News, Short Squeeze, Breakout and More Instantly...
New Age Brands Company Name:
MYCOF Stock Symbol:
OTCMKTS Market:
(TheNewswire) Vancouver, British Columbia – TheNewswire - May 16, 2024— Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order gr...
(TheNewswire) VANCOUVER, British Columbia – TheNewswire - May 2, 2024 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has requested a temporary Management Cease Trade Orde...
(TheNewswire) VANCOUVER, British Columbia, May 2, 2024 ( The N ewswire ) — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has received a temporary Management Cease Trade O...